Evidence map›Paper›PMID 39036016›Full record

ArticleThe Pan African medical journal2024

Immunoglobulin G (IgG) specific responses to recombinant Qβ displayed MSP3 and UB05 in plasma of asymptomatic

Loveline Ngu, Herve Ouambo Fotso, Inès Nyebe, Jules Colince Tchadji, Georgia Ambada, Akeleke Ndah, Bloomfield Atechi, Abel Lissom, Philémon Etienne Atabonkeng, George Chukwuma and 10 more

Abstract read
In one paragraph

Article in The Pan African medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Loveline NguLaboratory of Vaccinology/Biobanking, Chantal Biya International Reference Center for Research on the Prevention and Management of HIV/AIDS, Yaounde, Cameroon.
Herve Ouambo FotsoLaboratory of Vaccinology/Biobanking, Chantal Biya International Reference Center for Research on the Prevention and Management of HIV/AIDS, Yaounde, Cameroon.
Inès NyebeLaboratory of Vaccinology/Biobanking, Chantal Biya International Reference Center for Research on the Prevention and Management of HIV/AIDS, Yaounde, Cameroon.
Jules Colince TchadjiLaboratory of Vaccinology/Biobanking, Chantal Biya International Reference Center for Research on the Prevention and Management of HIV/AIDS, Yaounde, Cameroon.
Georgia AmbadaLaboratory of Vaccinology/Biobanking, Chantal Biya International Reference Center for Research on the Prevention and Management of HIV/AIDS, Yaounde, Cameroon.
Akeleke NdahPan African Center for Clinical and Translational Sciences (PANECTS), Yaounde, Cameroon.
Bloomfield AtechiPan African Center for Clinical and Translational Sciences (PANECTS), Yaounde, Cameroon.
Abel LissomLaboratory of Vaccinology/Biobanking, Chantal Biya International Reference Center for Research on the Prevention and Management of HIV/AIDS, Yaounde, Cameroon.
Philémon Etienne AtabonkengDepartment of Biochemistry, University of Dschang, Dschang, Cameroon.
George ChukwumaDepartment of Medical Laboratory Science, College of Health Sciences, Nnamdi Azikiwe University, Awka, Nigeria.
Vitalis EfezeuhDepartment of Biochemistry and Molecular Biology, University of Buea, Buea, Cameroon.
Park Chae GyuLaboratory of Immunology, Brain Korea 21 PLUS Project for Medical Science, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
Charles EsimoneDepartment of Pharmaceutical Microbiology and Biotechnology, Nnamdi Azikiwe University, Awka, Nigeria.
Jules Clement Assob NguediaDepartment of Medical Laboratory Sciences, University of Buea, Buea, Cameroon.
Eric Achidi AkumDepartment of Medical Laboratory Sciences, University of Buea, Buea, Cameroon.
Malachy OkekeDepartment of Natural and Environmental Sciences, Biomedical Science Concentration, School of Arts and Sciences, American University of Nigeria, 98 Lamido Zubairu Way, Yola, Nigeria.
Vincent Pryde Kehdingha TitanjiBiotechnology Units, Department of Biochemistry and Molecular Biology, University of Buea, Buea, Cameroon.
Wilfred MbachamDepartment of Biochemistry, Faculty of Sciences, University of Yaounde I, Yaounde, Cameroon.
Alain Bopda-WaffoPan African Center for Clinical and Translational Sciences (PANECTS), Yaounde, Cameroon.
Godwin Nchinda WapimewahLaboratory of Vaccinology/Biobanking, Chantal Biya International Reference Center for Research on the Prevention and Management of HIV/AIDS, Yaounde, Cameroon.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: in areas with intense perennial malaria transmission, limited data is available on the impact of environmental conditions especially rainfall on naturally acquired immunity against promising malaria vaccine candidates. For this reason, we have compared IgG antibody responses specific to Plasmodium spp. derived MSP3 and UB05 vaccine candidates, in plasma of children living in two areas of Cameroon differing in rainfall conditions. Methods: data about children less than 5 years old was collected during the years 2017 and 2018. Next malaria asymptomatic P. falciparum (Pf) infected children were selected following malaria test confirmation. MSP3 and UB05 specific IgG antibody responses were measured in participant´s plasma using enzyme-linked immunosorbent assay (ELISA). Results: interestingly, IgG antibody responses specific to UB05 were significantly higher (p<0.0001) in Pf-negative children when compared to their asymptomatic Pf-infected counterparts living in monomodal rainfall areas. In contrast, a significantly higher (p<0.0001) IgG response to MSP3 was observed instead in asymptomatic Pf-infected children in the same population. In addition, IgG responses specific to UB05 remained significantly higher in bimodal when compared to monomodal rainfall areas irrespective of children´s Pf infection status (p<0.0055 for Pf-positive and p<0.0001 for negative children). On the contrary, IgG antibody responses specific to MSP3 were significantly higher in bimodal relative to monomodal rainfall areas (P<0.0001) just for Pf-negative children. Conclusion: thus IgG antibody responses specific to UBO5 are a better correlate of naturally acquired immunity against malaria in Pf-negative Cameroonian children especially in monomodal rainfall areas.

Indexed as

Antibodies, ProtozoanAntigens, ProtozoanEnzyme-Linked Immunosorbent AssayImmunoglobulin GMalaria, FalciparumPlasmodium falciparumProtozoan ProteinsCameroonChild, PreschoolFemaleHumansInfantMalaria VaccinesMaleRainRecombinant ProteinsAntibodies, ProtozoanAntigens, ProtozoanImmunoglobulin GMalaria Vaccinesmerozoite surface protein 3, PlasmodiumProtozoan ProteinsRecombinant ProteinsAsymptomatic Plasmodium-infected childrenbimodalmonomodalQβMSP3QβUB05rainfall

Identifiers

PMID39036016
PMCPMC11260061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.